Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 14, Number 3—March 2008
Research

Multicenter Cross-Sectional Study of Nontuberculous Mycobacterial Infections among Cystic Fibrosis Patients, Israel

Isaac Levy*1, Galia Grisaru-Soen*12, Liat Lerner-Geva†, Eitan Kerem‡, Hana Blau§, Lea Bentur¶, Micha Aviram#, Joseph Rivlin**, Elie Picard††, Anita Lavy‡‡, Yakov Yahav*, and Galia Rahav*Comments to Author 
Author affiliations: *Sheba Medical Center, Tel Hashomer, Israel; †Gertner Institute for Epidemiology and Health Policy Research, Tel Hashomer, Israel; ‡Hadassah Hebrew University Hospital, Jerusalem, Israel; §Schneider Children’s Medical Center of Israel, Petah Tikva, Israel; ¶Rambam Medical Center, Haifa, Israel; #Soroka University Hospital, Beer Sheva, Israel; **Carmel Medical Center, Haifa, Israel; ††Shaare Zedek Medical Center, Jerusalem, Israel; ‡‡Mycobacterium Reference Laboratory of Israel, Tel Aviv, Israel; 1These authors contributed equally to this work.; 2Current affiliation: Dana Children’s Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.;

Main Article

Table 4

Comparison of patients with NTM infection and NTM disease according to 1997 and 2007 ATS criteria*

Parameter 1997 criteria
2007 criteria
NTM disease 
(n = 12) NTM infection (n = 30) p value NTM disease 
(n = 20) NTM infection 
(n = 22) p value
Age, y (mean ± SD) 19.8 ± 9.1 26.0 ± 11.2 0.17 24.2 ± 11.7 24.3 ± 10.4 0.97
Sex, F/M 7/5 11/19 0.20 9/11 9/13 0.79
No. sputum specimens (mean ± SD) 9.0 ± 5.1 4.4 ± 4.0 0.01 8.0 ± 5.2 3.6 ± 3.2 0.003
BMI, kg/m2 (mean ± SD) 18.9 ± 1.4 20.4 ± 4.0 0.19 19.7 ± 2.6 20.2 ± 4.1 0.63
Hemoptysis 4 6 0.36 6 4 0.37
FEV1, L/s (mean ± SD) 55.0 ± 23.0 57.4 ± 18.4 0.75 50.7 ± 20.3 62.1 ± 17.6 0.06
Pancreatic insufficiency 9 26 0.36 17 18 0.78
Sweat chloride (Meq/L) (mean ± SD) 66.5 ± 53.3 75.7 ± 49.6 0.61 81.9 ± 45.6 65.0 ± 53.7 0.28
Hospitalization, d (mean ± SD) 50.8 ± 52.5 26.2 ± 27.7 0.05 43.9 ± 44.1 23.6 ± 28.0 0.09
Administration of antimicrobial drug therapy, d (mean ± SD) 87.8 ± 110.9 34.7 ± 57.1 0.14 70.1 ± 90.6 31.5 ± 62.7 0.12
Azithromycin 10 20 0.55 15 15 0.63
Azithromycin treatment, d (mean ± SD) 379.5 ± 258.6 362.9 ± 322.7 0.87 360.7 ± 297.5 374.0 ± 314.2 0.89
Ibuprofen 4 1 0.01 4 1 0.12
Insulin 1 3 0.87 2 2 0.92
Systemic steroids 2 1 0.13 2 1 0.49
Inhaled steroids 10 16 0.07 16 10 0.02
AFB in sputum 7 4 0.01 8 3 0.05
Pseudomonas aeruginosa 12 28 0.36 20 20 0.17
Staphylococcus aureus 7 11 0.2 8 10 0.72
Aspergillus spp. 11 17 0.03 16 12 0.12
Allergic bronchopulmonary aspergillosis 3 0 0.004 3 0 0.06
Hemophillus influenza 2 1 0.14 2 1 0.52
Klebsiella pneumoniae 1 2 0.85 2 1 0.55
Stenotrophomonas maltophilia 2 0 0.02 2 0 0.14

*NTM, nontuberculous mycobacteria; ATS, American Thoracic Society; SD, standard deviation; BMI, body mass index; FEV1, forced expiratory volume in 1 s; AFB, acid-fast bacilli.

Main Article

1These authors contributed equally to this work.

2Current affiliation: Dana Children's Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

Page created: July 07, 2010
Page updated: July 07, 2010
Page reviewed: July 07, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external